{"id":1669,"date":"2015-01-13T13:15:41","date_gmt":"2015-01-13T13:15:41","guid":{"rendered":"http:\/\/ingelyt.com\/en\/?p=1669"},"modified":"2017-11-14T19:32:21","modified_gmt":"2017-11-14T19:32:21","slug":"new-ema-guide-definition-limits-exposition-risk-analysis-multiproduct-installations","status":"publish","type":"post","link":"https:\/\/ingelyt.com\/en\/blog\/new-ema-guide-definition-limits-exposition-risk-analysis-multiproduct-installations\/","title":{"rendered":"New EMA Guide: Definition of the limits of exposition for the risk analysis in multiproduct installations"},"content":{"rendered":"

1.Introduction<\/strong><\/b><\/h2>\n

 <\/p>\n

The EMA has approved\u00a0on the\u00a020th of November 2014,<\/strong>\u00a0the new guide \u201cGuideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities\u201d.<\/strong>\u00a0Once approved, this guide will have to be complied from the first of June 2015.<\/p>\n

\u00a0Download guide<\/a><\/address>\n

2.Goal<\/strong><\/b><\/h1>\n

 <\/p>\n

As indicated in the\u00a0guideline, the goal of this guide is to define the way the pharmacological and toxicological data of the different active substances have to be revised and evaluated, with a double aim:<\/p>\n